FDA to request Sarepta Therapeutics halt shipments of Duchenne gene therapy
The FDA will request Sarepta Therapeutics stop all shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy, following two deaths tied to the product.
Related Articles
An overlooked demographic has the highest suicide risk — and it’s been rising
The people most at risk from suicide aren’t adolescents in angst or those experiencing a midlife lull, but men age 75 and older.
GOP tax law will increase overdose deaths by 1,000 each year, analysis finds
Losing access to addiction medications doubles overdose risk. A new analysis says projected Medicaid cuts could add 1,000 opioid deaths yearly.
STAT readers weigh in on marijuana-related vomiting, drug prices, and more
“Our health care system needs to do a better job of diagnosing and supporting people with cannabis-related diseases,” a physician writes in response to a…
A sloppy report on mifepristone is being used to undermine the FDA — and the biotech industry
More than 50 biotech leaders and investors are urging the FDA to disregard a methodologically flawed report on mifepristone.
FDA to request Sarepta Therapeutics halt shipments of Duchenne gene therapy
The FDA will request Sarepta Therapeutics stop all shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy, following two deaths tied to the product.
We are mothers of Duchenne patients. Recent setbacks with Sarepta must not stop progress
Despite the risks of gene therapy, “we chose the risk of action over reticence,” write two Duchenne mothers.
FDA to request Sarepta Therapeutics halt shipments of Duchenne gene therapy
The FDA will request Sarepta Therapeutics stop all shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy, following two deaths tied to the product.
Up and down the ladder: The latest comings and goings
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
After second Sarepta death, Duchenne muscular dystrophy community is racked by recrimination and worry
Another gene therapy death of a Duchenne patient has some parents and doctors criticizing the FDA’s actions, even as other parents still push for the…
FDA to request Sarepta Therapeutics halt shipments of Duchenne gene therapy
The FDA will request Sarepta Therapeutics stop all shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy, following two deaths tied to the product.